Savara reports improved pulmonary gas transfer with daily molgramostim in post-hoc analysis of Phase 2/3 IMPALA trial patients with mild diffusion impairment
Observed price moves
- SVRA-0.21%10 min after this headline
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.